New molecular entities (NMEs) finally got back into the approval action after a drought of more than a month, as the US FDA gave the nod to Sage Therapeutics Inc.'s Zulresso (brexanolone) and Jazz Pharmaceuticals PLC's Sunosi (solriamfetol) as the fourth and fifth novel approvals of 2019.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?